Cryogenesis Biotechnology
Cryogenesis Biotechnology is a São Paulo-based private Brazilian biotech that provides cryogenic stem cell storage and regenerative medicine services — including umbilical cord blood, cord tissue, dental pulp, and semen cryopreservation plus PRP and apheresis therapies — primarily to expectant families, fertility patients, and healthcare providers across Brazil.
- Company typePrivate
- Founded1997
- HeadquartersSanto Antônio, Brazil
- Headcount51–100
- GTM typeB2C
- OfferingServices
What Cryogenesis Biotechnology does
Criogênesis (Cryogenesis Biotechnology) is a privately held Brazilian biotechnology company headquartered in São Paulo that specializes in stem cell cryopreservation and regenerative medicine. Founded circa 1997, it operates with 51–100 employees from a single São Paulo facility (Rua Américo Brasiliense, 1000, Chácara Santo Antônio) and is one of only three private cord blood banks in Brazil holding AABB international accreditation, alongside ISO 9001:2015 quality certification. The company's core offering is subscription-based cryogenic storage of biological materials — specifically hematopoietic stem cells from umbilical cord blood (SCU), mesenchymal stem cells from umbilical cord tissue (TCU), mesenchymal stem cells from deciduous tooth pulp, and semen for fertility preservation — complemented by regenerative medicine services including platelet-rich plasma (PRP) therapy, therapeutic apheresis, and extracorporeal photopheresis. Underlying technology centers on -196°C liquid nitrogen cryopreservation, apheresis-based cell separation (adopted 1997), a complete digestion method for tissue processing, and the ISBT 128 international identification standard that enables cross-border sample traceability.
The business model is direct-to-consumer, charging annual recurring storage fees to families for the indefinite preservation of biological samples collected at point-of-care. Distribution is built on exclusive-style collection partnerships with tier-1 maternity hospitals (Pro Matre, Santa Joana) for cord blood/tissue capture at childbirth, supplemented by a pediatric dentist network for dental pulp collection. Customer acquisition relies on a top-of-funnel mix of free in-person and online pregnancy courses (Curso de Gestantes), an "In Foco" educational newsletter, content marketing, and hospital-driven referrals during the childbirth window. Pricing is not publicly disclosed and is handled through a 24-hour 0800 hotline and direct contact.
More recently, the company has invested in clinical research credibility, notably a 2025 scientific collaboration with Hospital das Clínicas da Faculdade de Medicina da USP on mesenchymal stem cell applications in rotator cuff repair surgery, co-authored by its scientific director Dr. Nelson Tatsui. This positions Criogênesis to potentially extend its addressable scope from pure storage services into therapeutic regenerative medicine applications, though current operations remain centered on the Brazilian Southeast market. The company discloses no funding rounds, no M&A activity, and no parent-company structure, operating as a single legal entity under CNPJ 07.796.165/0001-60.
Cryogenesis Biotechnology firmographics
Firmographics- Name
- Cryogenesis Biotechnology
- Legal name
- Criogênesis
- Website
- https://criogenesis.com.br
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cryogenesis Biotechnology is a São Paulo-based private Brazilian biotech that provides cryogenic stem cell storage and regenerative medicine services — including umbilical cord blood, cord tissue, dental pulp, and semen cryopreservation plus PRP and apheresis therapies — primarily to expectant families, fertility patients, and healthcare providers across Brazil.
- Ownership category
- akta.pro rank
Cryogenesis Biotechnology industry classification
Industry- Product category
- Stem Cell Banking and Cryopreservation Services
- NAICS
- Blood and Organ Banks (621991), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where Cryogenesis Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Santo Antônio
- HQ country
- Brazil
- HQ region
- Latin America
Offices1 record
Markets served
Cryogenesis Biotechnology business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Cord Blood and Tissue Storage Services: Annual subscription-based storage fees for cryopreserved stem cells from umbilical cord blood and tissue, collected at birth. Families pay for collection, processing, and ongoing storage services.
- Dental Pulp Stem Cell Storage: Collection and cryopreservation services for stem cells from deciduous (baby) tooth pulp, stored for potential future regenerative medicine applications.
- Semen Cryopreservation: Semen collection and storage services for men with chronic diseases, fertility preservation before cancer treatment, or vasectomy.
- Platelet-Rich Plasma (PRP) Services: Production of growth factors and cells through apheresis technology for orthopedic, dental, ophthalmological, dermatological and plastic surgery applications in approved clinical contexts.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Cryogenesis Biotechnology product offering
Product offeringCore offering
Criogênesis provides cryopreservation and long-term storage services for stem cells collected from umbilical cord blood, umbilical cord tissue, and deciduous (baby) tooth pulp, complemented by semen cryopreservation, platelet-rich plasma (PRP) therapy, and therapeutic apheresis/photopheresis services. All biological material is processed and stored at its São Paulo laboratory under AABB-accredited and ISO 9001:2015-certified protocols for potential future regenerative and hematological treatments.
Product overview
Cryogenesis Biotechnology is a Brazilian biotechnology company specializing in stem cell storage, cryopreservation, and regenerative medicine. The core offering consists of four stem cell storage services: umbilical cord blood stem cells (SCU), umbilical cord tissue stem cells (TCU), dental pulp stem cells from deciduous teeth, and semen cryopreservation. These are complemented by regenerative medicine services including platelet-rich plasma (PRP) therapy, therapeutic apheresis, and extracorporeal photopheresis. The company also provides pregnancy education courses. All services operate under ISO 9001:2015 and AABB accreditation standards.
Differentiator
Problem solved
Functional benefit
Products and services
- Células-Tronco do Sangue do Cordão Umbilical (SCU) — Umbilical Cord Blood Stem Cell Storage Cryopreservation and long-term storage of hematopoietic stem cells harvested from umbilical cord blood at birth, intended for treatment of over 80 diseases including leukemias, lymphomas, thalassemia, and hereditary anemias. Sold to expectant families as a biological insurance service with recurring annual storage fees.
- Células-Tronco do Tecido do Cordão Umbilical (TCU) — Umbilical Cord Tissue Stem Cell Storage Cryopreservation of mesenchymal stem cells derived from umbilical cord tissue using a complete digestion/cell-culture method, providing cell count, viability, growth potential, and contamination data after processing. Sold to expectant families for regenerative medicine applications including tissue repair and immune modulation.
- Polpa do Dente de Leite — Deciduous Tooth Pulp Stem Cell Storage Collection and cryopreservation of mesenchymal stem cells from the pulp of naturally shed baby (deciduous) teeth, a non-invasive source of young stem cells with high regenerative potential. Sold to families of children aged roughly 5–12 as an additional biological storage option.
- Armazenamento de Sêmen — Semen Cryopreservation Cryopreservation of semen samples for men facing fertility risks from chronic diseases (e.g., diabetes, multiple sclerosis), patients about to undergo chemotherapy/radiotherapy, or men planning a vasectomy. Sold to individual male patients on a recurring annual storage fee model.
- PRP (Plasma Rico em Plaquetas) — Platelet-Rich Plasma Therapy Production of platelet-rich plasma via apheresis technology for tissue regeneration. Approved clinical applications include ophthalmology and dentistry; experimental/off-label use covers orthopedics, dermatology, and plastic surgery. Sold to medical practitioners and their patients.
- Aférese e Fotoferese — Therapeutic Apheresis and Extracorporeal Photopheresis Therapeutic apheresis services including plasmapheresis for antibody-mediated diseases (lupus, multiple sclerosis, Guillain-Barré syndrome) and extracorporeal photopheresis for T-cell mediated autoimmune diseases and transplant rejection. Sold to patients and referring physicians.
- Medicina Regenerativa — Regenerative Medicine Services Regenerative medicine service line that uses stem cells and cellular therapies to repair or replace damaged tissues and organs, including treatments targeting neurological diseases, diabetes, and orthopedic conditions. Sold to patients referred by specialists.
- Reprodução Humana — Human Reproduction Services Human reproductive medicine service line covering fertility preservation, assisted reproduction technologies, and genetic diagnostics. Sold to individuals and couples seeking fertility care.
Quantifiable outcome
- Over 60,000 cord blood transplants performed worldwide since 1988
- +1 more outcomes
Companies that use Cryogenesis Biotechnology
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Cryogenesis Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cryogenesis Biotechnology partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Hospital das Clínicas de São PaulocoreScientific research collaboration on mesenchymal stem cell applications in rotator cuff repair surgeries. Study led by Dr. Eduardo Angeli Malavolta with Dr. Nelson Tatsui (Criogênesis hematologist) as co-author. Published in scientific literature.
- Hospital Pro MatrecorePartnership for umbilical cord blood and tissue collection during childbirth at Hospital Pro Matre facilities. Criogênesis provides collection kits and processes samples at their laboratory.
- Hospital Santa JoanacorePartnership for umbilical cord blood and tissue collection during childbirth at Hospital Santa Joana. Criogênesis provides collection protocols and processes samples at their laboratory.
- Pediatric Dentist NetworkminorPartnership program for pediatric dentists (Cadastro de Parceria para Odontopediatria) to collect stem cells from deciduous teeth pulp.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Cryogenesis Biotechnology competitors and assessment
Company assessmentBroad incumbents
- Future Health Biobank: UK-headquartered stem cell bank with international operations across Europe and other regions. Comparable full-service cord blood, cord tissue, and dental pulp banking offering and global accreditations.
- Smart Cells International: UK-based private stem cell storage company offering cord blood and cord tissue banking with international shipping. Comparable B2C family-focused business model with global reach.
- StemCyte: International cord blood bank with both public and private banking programs. Comparable cryopreservation technology and accreditations, with a broader mix of public/private operations.
- ViaCord: Major U.S.-based cord blood and cord tissue bank owned by Revvity. Competes for the same high-trust family segment with a strong digital marketing and direct-to-consumer model.
- Americord Registry: U.S. private cord blood and tissue bank focused on expectant parents. Comparable subscription storage model with a strong direct-to-consumer digital acquisition approach.
- Cryo-Cell International: One of the largest publicly listed cord blood banks in the world and a direct global competitor for affluent families. Comparable service portfolio (cord blood + cord tissue storage) and an established international brand.
Direct peers
- CordVida: Brazilian private cord blood and cord tissue bank operating in the same customer segment (expectant families) with a comparable hospital-partnership model. Direct competitor in the São Paulo and broader Brazilian market.
- StemCorp: Brazilian cryopreservation and cellular therapy provider offering cord blood, cord tissue, and dental pulp stem cell banking. Operates in the same domestic regulatory environment and targets the same expectant-family demographic.
Others
- ControlLab: Brazilian laboratory quality-control partner of Cryogenesis. Included as an ecosystem enabler rather than direct competitor — relevant for understanding Cryogenesis's compliance infrastructure.
Regional players
- Crioestaminal: Portuguese/Iberian cord blood bank offering similar cord blood, cord tissue, and dental pulp storage services. Comparable model targeting expectant parents in a neighboring country to Cryogenesis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cryogenesis Biotechnology compliance and trust
Trust signalCompliance3 records
Cryogenesis Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cryogenesis Biotechnology leadership team
Management profileNumber of profiles
Profiles6 records
Cryogenesis Biotechnology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cryogenesis Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cryogenesis Biotechnology
What does Cryogenesis Biotechnology do?
Criogênesis provides cryopreservation and long-term storage services for stem cells collected from umbilical cord blood, umbilical cord tissue, and deciduous (baby) tooth pulp, complemented by semen cryopreservation, platelet-rich plasma (PRP) therapy, and therapeutic apheresis/photopheresis services. All biological material is processed and stored at its São Paulo laboratory under AABB-accredited and ISO 9001:2015-certified protocols for potential future regenerative and hematological treatments.
Is Cryogenesis Biotechnology a public or private company?
Cryogenesis Biotechnology is a private company. It is classified as unknown and is currently operating.
When was Cryogenesis Biotechnology founded?
Cryogenesis Biotechnology was founded in 1997. It employs 51 to 100 people.
Where is Cryogenesis Biotechnology based?
Cryogenesis Biotechnology is headquartered in Santo Antônio, Brazil, in the Latin America region.
How does Cryogenesis Biotechnology make money?
Four revenue lines are on record. Cord Blood and Tissue Storage Services are the primary driver. The others are dental Pulp Stem Cell Storage, semen Cryopreservation and platelet-Rich Plasma (PRP) Services.
Who are Cryogenesis Biotechnology's main competitors?
Broad incumbents on record are Future Health Biobank, Smart Cells International, StemCyte, ViaCord, Americord Registry and Cryo-Cell International. Direct peers are CordVida and StemCorp. ControlLab is listed as an others. Crioestaminal is listed as a regional player.
Does Cryogenesis Biotechnology have an API?
No public API is recorded for Cryogenesis Biotechnology.
What industry is Cryogenesis Biotechnology in?
Cryogenesis Biotechnology's product category is Stem Cell Banking and Cryopreservation Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 621991 and its SIC code is 2836.